Duba wurin da ke ƙasa sannan ka amsa tambayar daga baya a cikin harshe ɗaya kamar yadda wurin yake:  Matsayi: Ya zuwa shekarar 2019, hukumomin da ke tsarawa sun amince da magungunan sauya cututtukan guda goma sha biyu don sake dawowa-remitting multiple sclerosis (RRMS). Su ne interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, da kuma cladribine. Ba a bayyana tasirin farashin su ba a shekarar 2012. A watan Maris na 2017 FDA ta amince da ocrelizumab, wani maganin rigakafin anti-CD20 monoclonal antibody, a matsayin magani ga RRMS, tare da buƙatun gwaji na gwaji na Phase IV da yawa. A cikin RRMS suna da ƙarancin tasiri wajen rage yawan hare-hare. Interferons da glatiramer acetate sune magungunan farko kuma suna da kusan daidai, suna rage koma baya da kusan 30%. Farfadowa na dogon lokaci da aka fara da wuri ba shi da haɗari kuma yana inganta sakamako. Natalizumab yana rage yawan sake dawowa fiye da magungunan farko; duk da haka, saboda batutuwan sakamako masu illa shine magungunan layi na biyu wanda aka tanada ga waɗanda ba su amsa wasu jiyya ba ko tare da mummunan cuta. Mitoxantrone, wanda amfani da shi ya iyakance ta mummunan sakamako masu illa, shine zaɓi na uku ga waɗanda ba sa amsa wasu magunguna. Kula da cututtukan cututtukan cututtukan cututtukan cututtukan cututtuka (CIS) tare da interferons yana rage damar ci gaba zuwa MS na asibiti. Matsayin wasu sabbin magunguna kamar su fingolimod, teriflunomide, da dimethyl fumarate, kamar na 2011, har yanzu ba a bayyana su gaba ɗaya ba. Kamar na 2017, an yi amfani da rituximab sosai a waje da lakabi don magance RRMS.  Tambaya: Wane interferon ne aka ambata da farko?
interferon beta-1a